RMDN2 antisense RNA 1 (RMDN2-AS1)

RMDN2 antisense RNA 1 (RMDN2-AS1) is a long non-coding RNA (lncRNA) located on human chromosome 12 and transcribed from the opposite strand of the RMDN2 gene[1]. It does not encode a protein but participates in the regulation of gene expression, cell proliferation, apoptosis, and metabolic processes[1][2][4]. RMDN2-AS1 is implicated in cancer biology, particularly hepatocellular carcinoma, where it has been correlated with poor prognosis and may serve as a prognostic biomarker[2][4]. This lncRNA acts through complex co-expression networks, influencing metabolic adaptation, tumor progression, and apoptosis. While it is not a therapeutic target in the conventional sense (receptor, enzyme, transporter, etc.), it represents an emerging regulatory RNA of interest in cancer research[1][2][4]. There are no well-documented drug interactions or established mechanisms of drug action targeting RMDN2-AS1. Its precise biological roles are still under investigation, especially in the context of different cancers and possibly neurodegenerative diseases, where genetic loci encompassing RMDN2 have been linked to tau pathology in Alzheimer’s disease[6].